Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXCYTE, INC.MXCT · Entity 6608 | EVP, GLOBAL SALES | August 01, 2024 | August 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXCYTE, INC.
Report date August 01, 2024 · Filed August 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Ending reported balance
After 2024-08-02 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2024-08-01 · Exercise / conversion · Acquired 15,476 · Balance 40,476 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. Row 2 · 2024-08-01 · Sale · Disposed 15,476 · Balance 25,000 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F2: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.445 to $4.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2024-08-02 · Exercise / conversion · Acquired 17,857 · Balance 42,857 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. Row 4 · 2024-08-02 · Sale · Disposed 17,857 · Balance 25,000 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F3: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.235 to $4.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2030-01-20 | Direct | 17,858 |
Reported balance
After 2024-08-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-01 · Exercise / conversion · Disposed 15,476 · Balance 17,858 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F4: The option has fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.64 · Expires 2030-01-20 | Direct | 1 |
Reported balance
After 2024-08-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-08-02 · Exercise / conversion · Disposed 17,857 · Balance 1 F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F4: The option has fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024.
F2: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.445 to $4.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.235 to $4.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The option has fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2024 Filed Aug 5, 2024 18:57 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 17,857 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-24-020785 · form4-08052024_100803.xml · derivative · entry 6 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 17,857 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F4 · derivative.exercise_date: The option has fully vested. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 18:57 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 17,857 | $4.36 | $77,874.38 |
DisclosureSEC source: 0001415889-24-020785 · form4-08052024_100803.xml · nonDerivative · entry 4 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.235 to $4.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 18:57 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 17,857 | $1.64 | $29,303.34 |
DisclosureSEC source: 0001415889-24-020785 · form4-08052024_100803.xml · nonDerivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:57 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,476 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-24-020785 · form4-08052024_100803.xml · derivative · entry 5 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,858 Underlying: Common Stock · 15,476 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F4 · derivative.exercise_date: The option has fully vested. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:57 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 15,476 | $4.54 | $70,261.04 |
DisclosureSEC source: 0001415889-24-020785 · form4-08052024_100803.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.445 to $4.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 18:57 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 15,476 | $1.64 | $25,396.12 |
DisclosureSEC source: 0001415889-24-020785 · form4-08052024_100803.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. Read SEC document |
| July 09, 2024 Filed Jul 10, 2024 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,531 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-24-019463 · form4-07102024_040702.xml · derivative · entry 6 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 13,531 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F4 · derivative.exercise_date: The option has fully vested. Read SEC document |
| July 09, 2024 Filed Jul 10, 2024 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 13,531 | $4.03 | $54,584.05 |
DisclosureSEC source: 0001415889-24-019463 · form4-07102024_040702.xml · nonDerivative · entry 4 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.105, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2024 Filed Jul 10, 2024 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 13,531 | $1.64 | $22,204.37 |
DisclosureSEC source: 0001415889-24-019463 · form4-07102024_040702.xml · nonDerivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 19,802 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-24-019463 · form4-07102024_040702.xml · derivative · entry 5 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,865 Underlying: Common Stock · 19,802 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F4 · derivative.exercise_date: The option has fully vested. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 19,802 | $4.03 | $79,782.26 |
DisclosureSEC source: 0001415889-24-019463 · form4-07102024_040702.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.055, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 08, 2024 Filed Jul 10, 2024 16:15 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 19,802 | $1.64 | $32,495.08 |
DisclosureSEC source: 0001415889-24-019463 · form4-07102024_040702.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 16:17 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 33,333 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-24-017956 · form4-06242024_080648.xml · derivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 33,333 shares Expires 2030-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option has fully vested. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 16:17 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 33,333 | $4.09 | $136,465.30 |
DisclosureSEC source: 0001415889-24-017956 · form4-06242024_080648.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.00 to $4.185, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 16:17 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 33,333 | $1.64 | $54,699.45 |
DisclosureSEC source: 0001415889-24-017956 · form4-06242024_080648.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2024. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 18:21 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001415889-24-008640 · form4-03192024_100327.xml · derivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES & MARKETING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-03-14 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option shall vest on March 15, 2025, and the remainder shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 18:21 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008640 · form4-03192024_100327.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, GLOBAL SALES & MARKETING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Twenty-five percent (25%) of the RSUs shall vest on March 15, 2025, and the remainder shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| April 12, 2023 Filed Apr 12, 2023 17:03 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,583 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-024116 · doc4.xml · derivative · entry 9 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,868 Underlying: Common Stock · 5,583 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 12, 2023 Filed Apr 12, 2023 17:03 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 5,583 | $5.00 | $27,915.00 |
DisclosureSEC source: 0001209191-23-024116 · doc4.xml · nonDerivative · entry 6 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| April 12, 2023 Filed Apr 12, 2023 17:03 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 5,583 | $2.14 | $11,958.79 |
DisclosureSEC source: 0001209191-23-024116 · doc4.xml · nonDerivative · entry 5 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 17:03 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,451 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-024116 · doc4.xml · derivative · entry 8 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,451 Underlying: Common Stock · 8,451 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 17:03 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 8,451 | $5.00 | $42,255.00 |
DisclosureSEC source: 0001209191-23-024116 · doc4.xml · nonDerivative · entry 4 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 11, 2023 Filed Apr 12, 2023 17:03 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 8,451 | $2.14 | $18,102.04 |
DisclosureSEC source: 0001209191-23-024116 · doc4.xml · nonDerivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 17:03 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-024116 · doc4.xml · derivative · entry 7 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,902 Underlying: Common Stock · 100 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 17:03 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 100 | $5.00 | $500.00 |
DisclosureSEC source: 0001209191-23-024116 · doc4.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 17:03 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 100 | $2.14 | $214.20 |
DisclosureSEC source: 0001209191-23-024116 · doc4.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 16:43 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 27,193 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-023809 · doc4.xml · derivative · entry 6 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,002 Underlying: Common Stock · 27,193 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 16:43 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 27,193 | $5.03 | $136,780.79 |
DisclosureSEC source: 0001209191-23-023809 · doc4.xml · nonDerivative · entry 4 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 16:43 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 27,193 | $2.14 | $58,247.41 |
DisclosureSEC source: 0001209191-23-023809 · doc4.xml · nonDerivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 16:43 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,967 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-023809 · doc4.xml · derivative · entry 5 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,195 Underlying: Common Stock · 6,967 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 16:43 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 6,967 | $5.00 | $34,835.00 |
DisclosureSEC source: 0001209191-23-023809 · doc4.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 16:43 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 6,967 | $2.14 | $14,923.31 |
DisclosureSEC source: 0001209191-23-023809 · doc4.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| April 04, 2023 Filed Apr 4, 2023 19:00 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,266 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-022988 · doc4.xml · derivative · entry 9 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,162 Underlying: Common Stock · 7,266 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F4 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| April 04, 2023 Filed Apr 4, 2023 19:00 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 7,266 | $5.03 | $36,547.98 |
DisclosureSEC source: 0001209191-23-022988 · doc4.xml · nonDerivative · entry 6 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 04, 2023 Filed Apr 4, 2023 19:00 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 7,266 | $2.14 | $15,563.77 |
DisclosureSEC source: 0001209191-23-022988 · doc4.xml · nonDerivative · entry 5 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 19:00 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-022988 · doc4.xml · derivative · entry 8 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,428 Underlying: Common Stock · 100 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F4 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 19:00 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 100 | $5.01 | $501.00 |
DisclosureSEC source: 0001209191-23-022988 · doc4.xml · nonDerivative · entry 4 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 19:00 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 100 | $2.14 | $214.20 |
DisclosureSEC source: 0001209191-23-022988 · doc4.xml · nonDerivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 19:00 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,607 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-022988 · doc4.xml · derivative · entry 7 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,528 Underlying: Common Stock · 2,607 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F4 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 19:00 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 2,607 | $5.00 | $13,035.00 |
DisclosureSEC source: 0001209191-23-022988 · doc4.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 19:00 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 2,607 | $2.14 | $5,584.19 |
DisclosureSEC source: 0001209191-23-022988 · doc4.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 16:42 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001209191-23-020287 · doc4.xml · derivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-03-19 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on March 20, 2024 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 16:32 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,575 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-006880 · doc4.xml · derivative · entry 8 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,135 Underlying: Common Stock · 11,575 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F5 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 16:32 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 11,575 | $5.77 | $66,787.75 |
DisclosureSEC source: 0001209191-23-006880 · doc4.xml · nonDerivative · entry 5 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.69 to $5.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 16:32 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 11,575 | $2.14 | $24,793.65 |
DisclosureSEC source: 0001209191-23-006880 · doc4.xml · nonDerivative · entry 4 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:32 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,090 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-006880 · doc4.xml · derivative · entry 7 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,710 Underlying: Common Stock · 15,090 shares Expires 2029-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F5 · derivative.exercise_date: The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:32 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,468 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001209191-23-006880 · doc4.xml · derivative · entry 6 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,468 shares Expires 2026-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F4 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:32 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 17,558 | $5.68 | $99,729.44 |
DisclosureSEC source: 0001209191-23-006880 · doc4.xml · nonDerivative · entry 3 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.51 to $5.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:32 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 15,090 | $2.14 | $32,322.78 |
DisclosureSEC source: 0001209191-23-006880 · doc4.xml · nonDerivative · entry 2 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:32 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 2,468 | $0.98 | $2,426.04 |
DisclosureSEC source: 0001209191-23-006880 · doc4.xml · nonDerivative · entry 1 Ross Thomas M. · CIK 0001874572 · EVP, Global Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.